Impact News +++ Canadian Solar (CSIQ) Reports Q1 Loss, Beats Revenue Estimates (Zacks) +++ CANADIAN SOLAR Aktie -4,23%

REGENXBIO Aktie

>REGENXBIO Aktienkurs

7.164 EUR -16.5% (TradegateBSX)

Ask: 7.22 EUR / 315 Stück

Bid: 6.828 EUR / 330 Stück

Tagesumsatz: 1201 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

REGENXBIO Aktie über LYNX handeln

Intraday

1 Jahr

>REGENXBIO Performance

1 Woche: -1,7%

1 Monat: +10,5%

3 Monate: +25,6%

6 Monate: -16,1%

1 Jahr: +18,5%

laufendes Jahr: -30,5%

>REGENXBIO Aktie

Name:

REGENXBIO INC. DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US75901B1070 / A140E0

Symbol/ Ticker:

RB0 (Frankfurt) / RGNX (NASDAQ)

Kürzel:

FRA:RB0, ETR:RB0, RB0:GR, NASDAQ:RGNX

Index:

Webseite:

https://www.regenxbio.com..

Profil:

Regenxbio Inc. is a leading clinical-stage biotechnology company focused on developing and commercializing gene therapies to treat genetic disorders through its proprietary NAV Technology Platform. This platform utilizes recombinant adeno-associated ..
>Volltext..

Marktkapitalisierung:

442.59 Mio. EUR

Unternehmenswert:

468.52 Mio. EUR

Umsatz:

145.56 Mio. EUR

EBITDA:

-124.33 Mio. EUR

Nettogewinn:

-165.58 Mio. EUR

Gewinn je Aktie:

-3.21 EUR

Schulden:

222.49 Mio. EUR

Liquide Mittel:

29.43 Mio. EUR

Operativer Cashflow:

Bargeldquote:

1.95

Umsatzwachstum:

80.28%

Gewinnwachstum:

24.75%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 168.705 USD.

Suchwörter:

REGENXBIO

Letzte Datenerhebung:

14.05.26

>REGENXBIO Kennzahlen

Aktien/ Unternehmen:

Aktien: 51.62 Mio. St.

Frei handelbar: 89.24%

Leerverk. Aktien: 12.97%

Rückkaufquote: -0.19%

Mitarbeiter: 371

Umsatz/Mitarb.: 0.39 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 174.01%

Bewertung:

KGV: -

KGV lG: -

KUV: 3.22

KBV: 5.29

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 78.93%

Gewinnmarge: -113.75%

Operative Marge: -94.58%

Managementeffizenz:

Gesamtkaprendite: -42.19%

Eigenkaprendite: -107%

>REGENXBIO Peer Group

Gesundheit, Neurologie/ psychische Behandlung/ Schlaganfälle, Stoffwechselerkrankungen (Diabetes/ Adipositas), Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>REGENXBIO Chart & Kurs - NASDAQ

>REGENXBIO News

14.05.26 - 14:12	Regenxbio slides after late-stage trial data for Duchenne therapy (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.05.26 - 14:01	XFRA: RB0: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN REGENXBIO INC. DL-,0001 RB0 US75901B1070 AB/FROM ONWARDS 14.05.2026 13:52 CET...

14.05.26 - 13:24	XFRA: INSTRUMENT_SUSPENSION - US75901B1070 (XETRA)
	Instrument ID [10319] (RB0 - US75901B1070) suspended...

14.05.26 - 13:24	XFRA: RB0: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL REGENXBIO INC. DL-,0001 RB0 US75901B1070 BAW/UFN...

14.05.26 - 13:12	REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights (PR Newswire)
	Company announced positive topline results from pivotal Phase III AFFINITY DUCHENNE® study of RGX-202 Primary endpoint achieved with high statistical significance Statistically significant correlation between RGX-202 microdystrophin expression and functional improvement (NSAA, n=9),......

14.05.26 - 02:01	Insiderhandel: Chief Medical Officer verkauft Aktien von Regenxbio im Wert von 168705 USD (Insiderkauf)
	Pakola, Steve - Vorstand - Tag der Transaktion: 2026-05-11...

07.05.26 - 13:06	REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting (PR Newswire)
	ROCKVILLE, Md., May 7, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 2026 American Society of Gene & Cell Therapy Annual Meeting ("ASGCT 2026") taking place May 11-15, 2026, in Boston, Massachusetts. Oral Presentations: The oral presentations......

06.05.26 - 13:06	REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy (PR Newswire)
	-- Company will also report first quarter 2026 financial results and operational highlights -- ROCKVILLE, Md., May 6, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a webcast on Thursday, May 14, 2026, at 8:00 a.m. ET to discuss topline results from......

15.04.26 - 02:12	REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX (PR Newswire)
	LOS ANGELES, April 14, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder......

14.04.26 - 20:03	RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, April 14, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff......

14.04.26 - 18:12	Bronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm (Newsfile)
	New York, New York--(Newsfile Corp. - April 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed a......

13.04.26 - 06:03	RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, April 13, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange......

10.04.26 - 17:24	RGNX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like......

09.04.26 - 23:36	RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, April 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff......

06.04.26 - 10:06	RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange......

06.04.26 - 09:01	REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX (PR Newswire)
	LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by......

04.04.26 - 13:57	RGNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like......

03.04.26 - 22:33	RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, April 3, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff......

03.04.26 - 21:21	REGENXBIO, Inc. Class Action Reminder - Robbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights (PR Newswire)
	SAN DIEGO, April 3, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage......

30.03.26 - 10:21	RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, March 30, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wenn zwei Wesen, die miteinander durchs Leben gehen wollen, nichts als ihr Liebesgefühl haben, so sind ihre Quellen schnell erschöpft, und bald stellen sich Gleichgültigkeit, Übersättigung, Widerwille ein. - Honoré de Balzac

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram